|
Description
|
Value
|
Reference
|
|---|
| |
Base-case estimate
|
Range for sensitivity analysis
|
(reference for range)
|
|---|
| | |
Low
|
High
| |
|---|
|
Costs (2012 USD)
|
|
Disease costs
|
|
Medical costs
| | | | |
|
Mild malaria
| | | | |
|
Public health systems
|
0.51
|
0.26
|
0.77
|
[27] (±50%)
|
|
Households
|
0.50
|
0.21
|
1.00
|
[28] (±50%)
|
|
Severe malaria (CM, SMA)
| | | | |
|
Public health systems
|
12.76
|
6.38
|
19.14
|
[27] (±50%)
|
|
Households
|
0.50
|
0.21
|
1.00
|
[28] (±50%)
|
|
Non-medical costs
| | | | |
|
(Productivity costs)
|
|
Mild, CM, SMA
| | | | |
|
Adults
|
2.52
|
1.26
|
3.78
|
[16, 27] (±50%)
|
|
Children
|
1.11
|
0.56
|
1.67
|
[16, 27] (±50%)
|
|
Death
|
4.76
|
2.38
|
7.14
|
[16] (±50%)
|
|
Vaccine costs
|
|
Price per dose
|
7
|
1
|
15
|
[29, 30] (Min, Max)
|
|
Administration per dose
|
0.37
|
0.19
|
0.57
|
[30] (±50%)
|
|
Total costs for 3 doses
|
22.11
|
3.57
|
46.71
| |
|
LLINs costs
|
|
LLIN per two persons
|
3.16
|
2.23
|
5.23
|
[31, 32] (Min, Max)
|
|
DALY-related parameters
|
|
Life expectancy
|
47.1 years
| | |
[23]
|
|
Disability weights
| | | |
[33]
|
|
Mild malaria
|
0.191
|
0.172
|
0.211
| |
|
CM
|
0.471
|
0.443
|
0.471
| |
|
SMA
|
0.471
|
0.191
|
0.471
| |
|
Death
|
1
| | | |
|
Effectiveness parameters
|
|
Vaccine protection efficacy
|
|
Mild Malaria
|
0.539
|
0.496
|
0.578
|
[12] (95% CI)
|
|
Severe Malaria (CM, SMA)
|
0.313
|
0.142
|
0.448
|
[12] (95% CI)
|
|
Death
|
0.2
|
0.15
|
0.25
|
[19] (±25%)
|
|
Duration of protection
|
45 months
|
11 months
|
10 years
|
[14]
|
|
Vaccine coverage
|
0.85
|
0.64
|
0.99
|
[34, 35] (Min, Max)
|
|
LLIN protection efficacy
|
|
Mild Malaria
|
0.5
|
0.43
|
0.62
|
[36] (Min, Max)
|
|
Severe Malaria (CM, SMA)
|
0.45
|
0.2
|
0.63
|
[36] (95% CI)
|
|
Death
|
0.17
|
0.1
|
0.24
|
[36] (95% CI)
|
|
Duration of protection
|
3 years
|
3 years
|
5 years
|
[37] (Min, Max)
|
|
LLIN coverage
|
80%
|
55.4%
|
80%
|
[7] (Baseline (2010) - Target (2015))
|
|
LLIN use
|
88%
|
87%
|
90%
|
[38] (95% CI)
|
|
Discount rate%
|
3%
|
0%
|
6%
|
[39]
|
